Best Pharma Stocks in September 2026 Based on 5-Year CAGR: Neuland Laboratories, Wockhardt and More

In September 2026, the pharmaceutical sector showcased a range of stocks with impressive 5-year compound annual growth rates (CAGR). Leading the list are Neuland Laboratories Limited and Wockhardt Limited, among others, highlighting their growth in market capitalisation and returns. 

Top Pharma Stocks in September 2026 

Note: The above data is as of September 2, 2026. 

Neuland Laboratories Limited 

Neuland Laboratories Limited, with a market cap of ₹29,894.92 crore, recorded a last trade price of ₹23,025. Its price-to-earnings (PE) ratio stood at 82.13, with a 6-month return of 75.82% and a 1-year return of 71.84%. The company's 5-year CAGR was 71%, showcasing strong growth. 

Wockhardt Limited 

Wockhardt Limited, with a market cap of ₹30,650.9 crore, had a last trade price of ₹1,850.6. The PE ratio was 143.9, with a 6-month return of 41.27% and a 1-year return of 30.72%. The 5-year CAGR for Wockhardt was 38.02%. 

Suven Life Sciences Ltd 

Suven Life Sciences Ltd, with a market cap of ₹10,543.83 crore, recorded a last trade price of ₹381.6. Despite a negative PE ratio of -38.15, the company achieved a 6-month return of 168.75% and a 1-year return of 83.27%. Its 5-year CAGR was 37.14%. 

Glenmark Pharmaceuticals Limited 

Glenmark Pharmaceuticals Limited, with a market cap of ₹65,416.86 crore, had a last trade price of ₹2,470.4. The PE ratio was 48.04, with a 6-month return of 16.35% and a 1-year return of 28.21%. The 5-year CAGR was 35.94%. 

Marksans Pharma Ltd 

Marksans Pharma Ltd, with a market cap of ₹14,560.15 crore, recorded a last trade price of ₹322.4. The PE ratio was 34.84, with a 6-month return of 88.16% and a 1-year return of 92.63%. The 5-year CAGR was 35.3%. 

Read More: PVR INOX Share Price in Focus; Board Approves ₹300 Crore Share Buyback! 

Caplin Point Laboratories Ltd 

Caplin Point Laboratories Ltd, with a market cap of ₹19,465.08 crore, had a last trade price of ₹2,711.2. The PE ratio was 30.36, with a 6-month return of 62.07% and a 1-year return of 28.51%. The 5-year CAGR was 30.02%. 

Torrent Pharmaceuticals Ltd 

Torrent Pharmaceuticals Ltd, with a market cap of ₹1,86,247.12 crore, recorded a last trade price of ₹4,965.5. The PE ratio was 86.09, with a 6-month return of 13.65% and a 1-year return of 38.53%. The 5-year CAGR was 25.68%. 

Shilpa Medicare Ltd 

Shilpa Medicare Ltd, with a market cap of ₹15,938.94 crore, had a last trade price of ₹889.7. The PE ratio was 65.5, with a 6-month return of 174.98% and a 1-year return of 109.23%. The 5-year CAGR was 24.31%. 

Laurus Labs Ltd 

Laurus Labs Ltd, with a market cap of ₹97,364.26 crore, recorded a last trade price of ₹1,861.6. The PE ratio was 109.55, with a 6-month return of 74.8% and a 1-year return of 116.47%. The 5-year CAGR was 22.95%. 

Sun Pharmaceutical Industries Ltd 

Sun Pharmaceutical Industries Ltd, with a market cap of ₹4,56,449.48 crore, had a last trade price of ₹1,929. The PE ratio was 39.76, with a 6-month return of 10.07% and a 1-year return of 23.39%. The 5-year CAGR was 19.59%. 

Conclusion 

The top 10 pharma stocks in September 2026, led by Neuland Laboratories with a 5-year CAGR of 71%, highlight diverse growth rates. Wockhardt and Suven Life Sciences also showed strong performances with CAGRs of 38.02% and 37.14%, respectively. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.